[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urologic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urologic-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,45,79,121,146,177,198,223,253,280,308,344,363,385,419,440],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100642637","prediction-of-myocardial-injury-after-non-cardiac-surgery-in-urologic-cancer-patients-100642637",false,"NCT07634666","Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients","Prediction of Myocardial Injury After Major Non-Cardiac Surgery in Patients With Urologic Cancer: A Prospective Multicenter Observational Study","URO-MINS","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Patients scheduled for major non-cardiac surgery under general anesthesia due to urologic cancer (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy)\n* Patients who undergo preoperative standard 12-lead electrocardiography\n* Patients classified as having intermediate or higher surgical risk\n* Patients who can be followed for at least 30 days postoperatively\n* Patients who voluntarily provide written informed consent to participate in this study\n\nExclusion Criteria:\n\n* History of major adverse cardiovascular events (MACE) within 6 months prior to surgery\n* Inability to obtain essential clinical information required for study participation and follow-up\n* Patients who are not hospitalized after surgery\n* Individuals deemed inappropriate for participation in the study by the investigator due to legal or psychiatric reasons","ALL","60 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days after surgery in patients undergoing non-cardiac surgery for urologic cancer.",[25,26,27],"Myocardial Injury After Non-cardiac Surgery","Urologic Cancer","Major Adverse Cardiovascular Events (MACE)",[29,30,25,31,32,26],"Artificial Intelligence","Electrocardiography","Major Adverse Cardiovascular Events","Perioperative Cardiovascular Risk","NOT_YET_RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":21},"2026-06-01",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"Korea University Anam Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100495050","phase-4-fluid-challenge-and-plasma-volume-during-surgery-100495050","NCT05726136","Fluid Challenge and Plasma Volume, During Surgery","Comparison of Albumin and Ringer's Solution for Optimization of the Plasma Volume and Hemodynamics During Laparoscopic Surgery.","FC-VE","Inclusion Criteria:\n\n* Written consent to participate in the study\n* For women: relevant contraceptive, menopausal or a negative pregnancy test.\n* ASA category I to III\n* Laparoscopic abdominal surgery, with a duration of at least 90 minutes.\n* 18 to 85 years\n\nExclusion Criteria:\n\n* Patients with known cardiac failure\n* \\\u003C18 or \\>85 years\n* known allergy to albumin\n* extracellular hyperhydration or hypervolemia\n* kidney failure\n* pregnancy or planned pregnancy","18 Years","85 Years",{"count":56,"type":21},60,"INTERVENTIONAL",[59],"PHASE4","A short bolus infusion of fluid, called \"fluid challenge\" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml\u002Fkg body weight, albumin 5% 4 ml\u002Fkg body weight or albumin 20% 1 ml\u002Fkg body weight), using hemoglobin as a dilution indicator.",[62,26,63,64,65],"Colorectal Cancer","Gynecologic Cancer","Colorectal Disorders","Benign Neoplasm",[67],"laparoscopic surgery, fluid therapy, plasma volume","RECRUITING","2026-04-24",{"date":71,"type":37},"2026-04-30",{"date":73,"type":37},"2023-10-23",{"date":75,"type":21},"2026-10-31",{"name":77,"class":44},"Joachim Zdolsek",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":57,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":78},"100635881","extracellular-vesicles-and-chemotherapy-induced-peripheral-neuropathy-100635881","NCT07558447","Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy","Extracellular Vesicles as Predictive Biomarkers for Chemotherapy-Induced Peripheral Neuropathy","CHEMOVES","Inclusion Criteria:\n\n* Has signed the informed consent form\n* Is 18 years of age or older\n* Is male or female\n* Has breast cancer and is scheduled to receive paclitaxel, docetaxel, eribulin, capecitabine, or carboplatin as part of standard care\n* Has gastrointestinal cancer and is scheduled to receive oxaliplatin or capecitabine as part of standard care\n* Has lung cancer and is scheduled to receive cisplatin, carboplatin, or docetaxel as part of standard care\n* Has urologic cancer and is scheduled to receive carboplatin, cisplatin, paclitaxel, docetaxel, or enfortumab vedotin as part of standard care\n* Has head and neck cancer and is scheduled to receive carboplatin, paclitaxel, or cisplatin as part of standard care\n\nExclusion Criteria:\n\n* Has already been diagnosed with CIPN\n* Has a neurodegenerative disease",{"count":88,"type":21},120,[90],"NA","The goal of this clinical trial is to learn whether extracellular vesicles (EVs) in the blood can be used as biomarkers to predict chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer patients receiving chemotherapy with taxanes, platinum compounds, or antimitotic drugs. The main questions the study aims to answer are whether blood levels of EVs change in patients who develop CIPN during and after chemotherapy and whether specific features of EVs, including lipids and microRNAs, are associated with the development and severity of CIPN. Participants will be followed from before the start of chemotherapy until six months after treatment ends to evaluate how changes in EVs relate to nerve damage caused by chemotherapy. During the study, participants will provide blood samples before chemotherapy, at the end of treatment, and six months later for measurement and molecular analysis of EVs, will complete questionnaires about neuropathy symptoms, and will undergo simple, non-invasive nerve function tests using a tuning fork (diapason) and a Neuropen device. This study does not test cancer drugs; instead, it aims to identify biological markers in blood that may help predict which patients are at higher risk of developing CIPN, with the goal of improving monitoring and care during cancer treatment.",[93,94,95,96,26,97],"Chemotherapy-Induced Peripheral Neuropathy","Breast Cancer","Gastrointestinal Cancer","Lung Cancer","Head and Neck Cancer",[93,99,100,101,102,103,104,105,106,107,108,109,110,111,112],"Neurotoxicity","Extracellular Vesicles","Biomarkers","Liquid Biopsy","Paclitaxel","Docetaxel","Eribulin","Capecitabine","Carboplatin","Oxaliplatin","Cisplatin","Enfortumab Vedotin","Neuropathy","Cancer","2026-04-23",{"date":71,"type":37},{"date":116,"type":37},"2025-01-01",{"date":118,"type":21},"2026-09",{"name":120,"class":44},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":142,"locationsCount":145},"100550197","an-expanded-access-program-of-cretostimogene-grenadenorepvec-for-treatment-of-nmibc-for-patients-unresponsive-to-bcg-100550197","NCT06443944","An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG","An Expanded Access Program of Cretostimogene Grenadenorepvec in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)","Inclusion Criteria:\n\n1. Have pathologically confirmed BCG unresponsive CIS. There is no maximum limit to the amount of prior BCG treatment, but maintenance BCG should be administered on a schedule consistent with standard induction-maintenance protocols. Specifically, the definition of BCG unresponsive CIS will also require the following:\n\n   * Pathologically confirmed relapsed or persistent CIS (with or without HG Ta or HG T1 disease)\n   * Completion of qualifying BCG treatment (e.g., \"5+2\" minimum exposure) within 15 months of the initial qualifying dose of BCG.\n2. Have all Ta and\u002For T1 disease and all CIS resected or fulgurated, as feasible, prior to study treatment\n3. Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.\n4. Acceptable baseline organ function\n\nExclusion Criteria:\n\n1. Muscle invasive bladder cancer, locally advanced or metastatic bladder cancer.\n2. Has had active autoimmune or inflammatory disease requiring systemic treatment within 4 weeks of Day 1. Replacement therapy is not considered an excluded form of systemic treatment and is allowed.\n3. Has received systemic anticancer therapy, including investigational agents, within 4 weeks of Day 1\n4. Is pregnant, currently breastfeeding or intending to breastfeed, beginning at Screening through 1 week after the last study treatment.","EXPANDED_ACCESS","This is an open-label, expanded access trial designed to provide access to cretostimogene in patients with NMIBC (specifically CIS with or without HG Ta\u002FT1) unresponsive to BCG.",[131,132,26,133],"Non-Muscle Invasive Bladder Cancer","Urothelial Carcinoma","Bladder Cancer",[135,133,136,137],"Urology","Non Muscle Invasive Bladder Cancer","Cretostimogene Grenadenorepvec","AVAILABLE","2026-04-13",{"date":141,"type":37},"2026-04-14",{"name":143,"class":144},"CG Oncology, Inc.","INDUSTRY",26,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":57,"phases":156,"briefSummary":158,"conditions":159,"keywords":164,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100628630","phase-3-a-study-of-ndv-01-sustained-release-gemcitabine-docetaxel-in-participants-with-non-muscle-invasive-bladder-cancer-100628630","NCT07464145","A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer","A Phase 3 Study Evaluating the Efficacy and Safety of NDV-01 in Participants With Non-muscle Invasive Bladder Cancer (RESCUE)","RESCUE","Cohort 1 Inclusion Criteria:\n\n1. Be ≥18 years of age (or the legal age of majority in the jurisdiction in which the study is taking place) at the time of informed consent.\n2. Have a histologically confirmed diagnosis (within 90 days of randomization) of IR NMIBC based on the AUA\u002FSUO criteria of IR NMIBC (excluding LGT1 tumors).\n3. Participant must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence\u002Fprogression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm.\n4. Participant must have ≥ 1 IBCG risk factors: 1) multiple tumors, 2) early recurrence (within 1 year), 3) frequent recurrences (\\> 1 per year), 4) tumor size (\\> 3 cm), 5) failure of prior induction intravesical therapy.\n5. Visible papillary disease must be fully resected prior to randomization, and absence of disease must be documented at Screening cystoscopy. The same method for visualizing disease at Screening cystoscopy should be used throughout for the participant (white light versus enhanced cystoscopic method \\[e.g., blue light cystoscopy, narrow-band imaging\\]).\n\n   All pathology specimens must be predominantly urothelial (transitional cell) and have less than 20% variant (e.g., sarcomatoid, squamous component) histology.\n6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n\nCohort 1 Exclusion Criteria:\n\n1. Histologically confirmed stage T1 tumors.\n2. Histologically confirmed diagnosis of HR NMIBC (including CIS) or muscle-invasive bladder cancer (MIBC), locally advanced, nonresectable, or metastatic urothelial carcinoma at any time prior to enrollment.\n3. Has had urothelial carcinoma outside of the urinary bladder (including prostatic urethra, ureter, or renal pelvis) or has a predominant histological variant of urothelial carcinoma (UC). Ta\u002Fany T1, CIS of the upper urinary tract is allowable if treated with complete nephroureterectomy more than 24 months prior to initiating study.\n4. Participant has tumor(s) involving the prostatic urethra (ductal or stromal).\n5. N+ and\u002For M+ per computed tomography (CT)\u002Fmagnetic resonance (MR) urography.\n6. Received an investigational treatment for bladder cancer within 6 months prior to randomization, before the planned first dose of study treatment, or is currently enrolled in an investigational study.\n7. Received adjuvant induction intravesical chemotherapy within 3 months of current diagnosis. Peri-operative instillation of a single dose of intravesical chemotherapy is allowed per institutional guidelines.\n8. Received prior intravesical treatment with immunotherapy, including BCG, within 3 months prior to randomization.\n\nCohort 2 Inclusion Criteria:\n\n1. Cohort 2a: BCG-unresponsive NMIBC with CIS of the bladder, with or without coexisting papillary Ta\u002FT1 tumor(s) who are ineligible for or have elected not to undergo cystectomy at the time of enrollment and have received 1 or 2 lines of therapy after meeting criteria for BCG unresponsiveness and experienced biopsy confirmed CIS disease within 12 months of last treatment, where:\n\n   * Adequate BCG regimen consists of at least 2 courses of BCG, where the first course (induction) must have included at least 5 of 6 doses and the second course may have included a re-induction (at least 2 of 6 treatments) or maintenance (at least 2 of 3 doses). Adequacy of the BCG regimen will be determined by the Investigator in conjunction with the Sponsor.\n   * Treatment after BCG unresponsiveness includes either approved or in development therapy\n   * Post-treatment presence of CIS must be documented or indicated by pathology at screening or within 4 months of screening (provided no therapy for CIS disease was given after the most recent biopsy).\n   * For inclusion, a participant with BCG-unresponsive disease (as defined above) must have received up to two lines of therapy for BCG-unresponsive disease and who are being considered for radical cystectomy. Such therapies may include agents approved or in development (e.g., pembrolizumab, nadofaragene firodenovec, nogapendekin alfa inbakicept-pmln, cretostimogene grenadenorepvec, detalimogene voraplasmid, TARA-002, gemcitabine intravesical system (INLEXZO®), gemcitabine-docetaxel, gemcitabine, MMC, or valrubicin monotherapy. Participant will have demonstrated biopsy-proven recurrence with HG papillary disease (without CIS) after one or two first-line therapy(ies).\n2. Cohort 2b: BCG-unresponsive NMIBC of the bladder, with papillary Ta\u002FT1 tumor(s) and without co-existing CIS, who are ineligible for or have elected not to undergo cystectomy at the time of enrollment and have experienced recurrent Ta\u002FT1 disease within 12 months of treatment with 1 or 2 lines of therapy after BCG-unresponsive status.\n\n   * For inclusion, a participant with BCG-unresponsive disease (as defined above) must have received up to two lines of therapy for BCG-unresponsive disease and who are being considered for radical cystectomy. Such therapies may include agents approved or in development (e.g., pembrolizumab, nadofaragene firodenovec, nogapendekin alfa inbakicept-pmln, cretostimogene grenadenorepvec, detalimogene voraplasmid, TARA-002, gemcitabine intravesical system (INLEXZO®), gemcitabine-docetaxel, gemcitabine, MMC, or valrubicin monotherapy. Participant will have demonstrated biopsy-proven recurrence with HG papillary disease (without CIS) after one or two first-line therapy(ies).\n\nAll Cohort 2\n\n1. A participant with HG T1 may be eligible after repeat-TURBT showing non-invasive (Ta or less) or no disease. Either original or repeat-TURBT must confirm that muscularis propria is present and uninvolved in the specimen.\n2. All specimens must be predominantly urothelial (transitional cell) carcinoma with or without squamous or glandular differentiation. Pure squamous or glandular tumors will not be included. A participant with less than 10% micropapillary histology will be included. All other variant histology (e.g., plasmacytoid, small cell, nested, trophoblastic variants) will not be included.\n\nCohort 2 Exclusion Criteria:\n\n1. Has had urothelial carcinoma outside of the urinary bladder (i.e., urethra, ureter, or renal pelvis) or has a predominant histological variant of UC. Ta\u002Fany T1, CIS of the upper urinary tract is allowable if treated with complete nephroureterectomy more than 24 months prior to initiating study and is considered to be without evidence of recurrent disease.\n\n   * Participants have tumor(s) involving the prostatic urethra (ductal or stromal).\n   * N+ and\u002For M+ per computerized tomography (CT)\u002FMagnetic Resonance Imagery (MR) urography.\n2. History of prior T2\u002FT3 urothelial carcinoma of the bladder.\n3. Concurrent treatment with any chemotherapeutic agent.\n4. Intravesical chemotherapy within 3 months of enrollment (including INLEXZO®, gemcitabine-docetaxel)",{"count":155,"type":21},393,[157],"PHASE3","Study REL-NDV01-303 is a Phase 3, open-label, multi-center study to determine the safety and efficacy of NDV-01 in adult participants with NMIBC. The study will include two cohorts:\n\n* Cohort 1: a randomized, open-label, parallel group, multi-center, Phase 3 study evaluating the efficacy and safety of the NDV-01 versus observation in participants with histologically confirmed IR-NMIBC.\n* Cohort 2: an open-label, multi-center, single-arm Phase 3 study evaluating the efficacy and safety of the NDV-01 in two populations of high-risk NMIBC:\n\n  * Cohort 2a: will include participants with HR-NMIBC who have a biopsy-proven recurrence with CIS ± papillary disease after receiving one or 2 lines of therapy for BCG-unresponsive NMIBC (approved or in development).\n  * Cohort 2b: will include participants with high-risk papillary-only disease (without CIS) NMIBC who have a biopsy-proven recurrence with HG papillary disease after receiving one or 2 lines of therapy for BCG-unresponsive NMIBC (approved or in development).\n\nThis study will evaluate the safety and efficacy of intravesical administration of NDV-01, and its effect on disease recurrence and progression in patients with NMIBC who have IR disease and have recently undergone a TURBT (Cohort 1) and in patients who have HR BCG-unresponsive disease and who have recurred after first-line therapy for BCG-unresponsive patients - both approved and in development - and are unwilling or unable to undergo radical cystectomy (Cohort 2). Both GEM and DOCE have established safety and efficacy across a range of tumor types, including IR and BCG-unresponsive NMIBC. By combining both GEM and DOCE in an intravesical extended-release formulation, Relmada believes that NDV-01 has the potential to be an agent for second-line therapy in patients who have recurred after first-line therapy in BCG-unresponsive disease, thereby avoiding radical cystectomy. This study will serve as a master protocol for all cohorts included in the study.",[160,161,162,163,26],"Bladder (Urothelial, Transitional Cell) Cancer","Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)","Urothelial Carcinoma Bladder","Urothelial Carcinoma Recurrent",[165,166,167],"NMIBC","non-muscle-invasive bladder cancer","bladder cancer","2026-03-05",{"date":170,"type":37},"2026-03-11",{"date":172,"type":21},"2026-06",{"date":174,"type":21},"2032-09",{"name":176,"class":144},"Relmada Therapeutics, Inc.",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":57,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":78},"100624976","web-based-application-for-monitoring-radiation-therapy-complications-in-cancer-patients-100624976","NCT07416630","Web-Based Application for Monitoring Radiation Therapy Complications in Cancer Patients","Programme for Development and Use of a Web-based Application for Monitornig Complications of Radiation Therapy in Cancer Patients and Analysis of Its Effectiveness","Inclusion Criteria:\n\n* Patients receiving radiotherapy for gynecologic cancer, urologic cancer, or breast cancer at the Institute of Oncology Ljubljana.\n* Ability to access and use the web-based application on a smartphone, computer, or tablet.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Inability to understand the questionnaire questions and provide meaningful answers.",{"count":185,"type":21},30,[90],"Cancer treatment is multidisciplinary and may include radiotherapy. Treatment-related complications represent a burden for patients and the healthcare system. Early recognition of radiotherapy-related side effects is important for timely clinical interventions and improved quality of care. This study aims to improve comprehensive patient management during and after radiotherapy through development and implementation of a web-based application using standardized electronic patient-reported outcome questionnaires (PROMs). Patients will report radiotherapy-related symptoms and quality of life through web-based questionnaires that will be securely transmitted to the Institute of Oncology Ljubljana for review by healthcare professionals. Responses will be categorized using a traffic-light system to guide clinical actions and optimize follow-up visits.",[63,26,94],"2026-02-20",{"date":191,"type":37},"2026-02-24",{"date":193,"type":37},"2023-09-02",{"date":195,"type":21},"2026-12-31",{"name":197,"class":44},"Institute of Oncology Ljubljana",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":57,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100612384","interest-of-magnetic-resonance-imaging-in-the-diagnosis-of-upper-urinary-tract-invasive-tumours-100612384","NCT07252882","Interest of Magnetic Resonance Imaging in the Diagnosis of Upper Urinary Tract Invasive Tumours","UUTICaD","Inclusion Criteria:\n\n* Patient over 18 years of age with a suspected upper urinary tract tumour based on the presence of a suspicious lesion on a uro-computed tomography scan\n* Have given free, informed and signed consent\n* Be affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Renal failure not allowing the injection of iodinated contrast media (Glomerular filtration rate \\\u003C30mL\u002Fmin)\n* Subject under legal protection (guardianship or curatorship)\n* Pregnant or breastfeeding woman\n* Person participating in another research study or having participated in a protocol with an exclusion period still in progress at inclusion\n* Contraindication to magnetic resonance imaging (patient with non-magnetic resonance imaging compatible equipment, claustrophobia preventing magnetic resonance imaging)\n* Acide gadoteric hypersensibility",{"count":206,"type":21},178,[90],"Upper urinary tract invasive cancer magnetic resonance imaging diagnosis",[210,26],"Magnetic Resonance Imaging (MRI)",[212],"Upper urinary tract magnetic resonance imaging","2025-11-26",{"date":215,"type":37},"2025-11-28",{"date":217,"type":21},"2025-12-01",{"date":219,"type":21},"2027-12-31",{"name":221,"class":44},"University Hospital, Toulouse",11,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":230,"minAge":53,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":57,"phases":233,"briefSummary":234,"conditions":235,"keywords":241,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":78},"100609582","vaginal-dilator-therapy-after-pelvic-radiation-100609582","NCT07216456","Vaginal Dilator Therapy After Pelvic Radiation","Improving Engagement With Vaginal Dilator Therapy After Pelvic Radiation: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* female sex\n* adults aged 18 years or older\n* diagnosed with cancer of the anus, anal canal, anorectum, cervix, uterus, vagina, vulva, and\u002For bladder\n* completed pelvic radiation therapy in the past year\n* dilator therapy recommended by medical provider and standardized dilator received from provider\n* able to speak\u002Fread English\n\nExclusion Criteria:\n\n* aged less than 17 years\n* under the care of a pelvic floor physical therapist at the time of study enrollment\n* have a major\u002Fserious psychiatric concern (e.g., schizophrenia) as indicated by medical chart\u002Fmedical provider\n* inability to provide consent","FEMALE",{"count":232,"type":21},88,[90],"This study is testing a new program to help women who have had pelvic radiation therapy to use vaginal dilators more regularly. Vaginal dilators are important tools that can help prevent or treat vaginal narrowing (called vaginal stenosis), which can happen after radiation and make medical exams or sexual activity painful or difficult. Even though dilators are recommended, many women don't use them as often as needed.\n\nIn this study, 88 participants will be randomly assigned to one of two groups:\n\n* One group will receive the new behavioral program, which includes support and strategies to help with regular dilator use.\n* The other group will receive written educational materials (enhanced usual care).\n\nThe study will look at how often and how long participants use their dilators, and whether the program helps reduce symptoms like pain or emotional distress. Participants will complete surveys at the beginning of the study and again at 3, 6, and 9 months, plus short monthly check-ins.\n\nThe goal is to see if the program is helpful and easy to use, and to prepare for a larger study in the future.",[236,237,238,239,240,26],"Pelvic Radiotherapy","Vaginal Stenosis","Pelvic Cancer","Gynecologic Cancers","Anorectal Cancer",[242,243],"vaginal dilator therapy","pelvic radiation","2025-10-13",{"date":246,"type":37},"2025-10-15",{"date":248,"type":21},"2027-08-01",{"date":250,"type":21},"2030-04-30",{"name":252,"class":44},"Duke University",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":57,"phases":262,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":78},"100509969","phase-2-vte-prevention-with-rivaroxaban-in-genitourinary-cancer-patients-receiving-systemic-therapy-100509969","NCT05920343","VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy","Prevention of Thromboembolism With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial","PREVENT-GU","Inclusion Criteria:\n\n* Patients who are starting systemic therapy for active GU cancer (bladder, testis, ureter\u002Frenal pelvis, kidney, urethral, penile) except for prostate cancer.\n* Age ≥ 18\n* Eligible systemic therapies include chemotherapy, targeted therapies (tyrosine kinase inhibitors and antiangiogenic therapy), and immunotherapies.\n* Patients must be initiating systemic therapy with a minimum planned treatment duration of 8 weeks.\n\nExclusion Criteria:\n\n* Anticoagulation (prophylactic or therapeutic dosing) required for another indication for entire duration of study\n* Known allergies to rivaroxaban\n* Concomitant use of dual antiplatelet therapy (two antiplatelet medications oncomitantly)\n* Ongoing refractory bleeding that may be exacerbated by rivaroxaban.\n* Concomitant use of strong inducers or inhibitors of CYP3A4 or glycoprotein-P (known interaction with rivaroxaban).\n* Severe renal insufficiency (Creatinine clearance \\\u003C30 mL\u002Fmin (defined by Cockcroft-Gault))\n* Severe liver disease (e.g. acute clinical hepatitis, chronic active hepatitis, cirrhosis)\n* Thrombocytopenia \\\u003C 50 x 109\u002FL\n* Life expectancy under 6 months.\n* Pregnancy (if child bearing age under 50 and sexually active, documentation of use of effective contraception or negative B- HCG is required)\n* Patient is breastfeeding or lactating\n* History of condition at increased bleeding risk including, but not limited to:\n\ncerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the previous 4 weeks.\n\n* Chronic hemorrhagic disorder\n* Inability to adhere to protocol or obtain consent.\n* Patients may be excluded from the study for other reasons, at the investigator's discretion.",{"count":88,"type":21},[263,157],"PHASE2","Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy). Blood clots cause pain, may require hospitalization and invasive testing, and in some cases cause death. In fact, blood clots are one of the leading causes of death in patients with cancer. Furthermore, patients who develop a blood clot require medication to thin the blood for a prolonged (sometimes indefinite) period of time, and this can disrupt other important cancer treatments. Studies have shown that using low dose blood thinners to prevent blood clots during systemic therapy is effective in some patients with cancer. However very few patients in these studies had genitourinary cancers, therefore physicians in Canada are not sure if recommending blood thinners to patients with genitourinary cancers is useful or safe. Safety is a primary concern because blood thinners may cause bleeding, and patients with genitourinary cancers may have higher risk of bleeding than patients with other types of cancer. The investigators hypothesize that blood thinners are effective and safe for reducing blood clots in patients with genitourinary cancers. The objective of this study is to determine if a large clinical trial testing the effectiveness and safety of low dose blood thinners for preventing blood clots in patients with genitourinary cancers receiving systemic therapy is feasible.",[266,26],"Venous Thromboembolism",[268,266,269,270],"Genitourinary Cancer","Systemic Therapy","Thromboprophylaxis","2025-07-08",{"date":273,"type":37},"2025-07-10",{"date":275,"type":37},"2024-11-04",{"date":277,"type":21},"2026-10",{"name":279,"class":44},"Ottawa Hospital Research Institute",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":57,"phases":288,"briefSummary":289,"conditions":290,"keywords":291,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":222},"100546697","palliative-radiotherapy-in-symptomatic-pelvic-soft-tissue-tumors-100546697","NCT06398314","Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors","PALLSOFT","Inclusion Criteria:\n\n* Patients unsuitable for curative treatment due to either advanced disease or medical contradictions (i.e comorbidity, old age, poor general condition)\n* Histologically verified primary cancer originated from gastrointestinal, urological or gynecological organs (histological verification can be performed on other lesions than the symptomatic pelvic tumor)\n* Primary, residual, recurrent or metastatic pelvic tumor from the above-mentioned cancers not amenable for curative treatment\n* Tumor-related symptoms including within the 5 defined categories pain, bleeding, bowel\u002Flower urinary\u002Fvaginal dysfunction\n* Considered candidate for palliative radiotherapy according to both study arms\n* Patient reported severity of symptoms ≥4 on a NRS- scale of 0-10\n* ≥18 years of age\n* Speaks and understands Norwegian or English\n* Ability to understand and willing to sign a written informed consent\n* ECOG performance status 0-3\n* Expected survival \\> 12 weeks\n* Able to pause systemic cancer treatment for one week prior to, during, and one week after the radiotherapy treatment\n* Women of childbearing potential (WOCBP) should have a negative highly sensitive serum pregnancy test within 72 hours prior to study intervention. WOCBP must agree to the use of highly effective birth control methods or abstain from heterosexual sexual activity from randomization and until completed study intervention\n\nExclusion Criteria:\n\n* Neuroendocrine histology of any kind\n* Sarcoma or sarcomal components in the histology\n* Tumors that originate from bony metastases without a soft tissue component\n* Unable to comply with study questionnaires\n* Ongoing treatment with an investigational drug at inclusion\n* Planned inclusion in another interventional clinical trial within 4 weeks after radiotherapy\n* Patients who are pregnant due to risk of teratogenic and abortifacient effects of radiotherapy",{"count":20,"type":21},[90],"PALLSOFT is a randomized, open-label, non-inferiority phase III, multicenter, national trial that will investigate whether the patient-reported symptomatic effect of palliative radiotherapy delivered in 1-2 fractions is non-inferior to palliative radiotherapy delivered in five fractions in patients with pelvic soft tissue tumors from either gastrointestinal, urological or gynecological cancer. Health-related quality of life, toxicities, survival and prognostic and predictive biomarkers will be assessed as secondary and explorative endpoints.",[95,26,63],[292,293,294,295,296,297],"Palliative radiotherapy","Patient-reported outcomes","Gastrointestinal cancer","Urologic cancer","Gynecologic cancer","Tumor hypoxia","2025-05-22",{"date":300,"type":37},"2025-05-23",{"date":302,"type":37},"2024-12-10",{"date":304,"type":21},"2030-12",{"name":306,"class":307},"Sykehuset Telemark","OTHER_GOV",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":318,"conditions":319,"keywords":321,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":78},"100579695","in-depth-characterization-of-circulating-and-infiltrating-immune-subsets-and-tumor-cells-in-cancer-patients-100579695","NCT06827639","In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients","In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients.","FUTURE","Inclusion Criteria:\n\n* 18 years of age or older\n* Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications\n* Written informed consent signed from subject prior to performing any protocol-related procedures\n\nExclusion Criteria:\n\n* Use of any investigational agent within 14 days prior first visit;\n* Patient under guardianship\u002Ftrusteeship or legally incapacitated person;\n* Patient unable to understand read and\u002For sign an informed consent;\n* Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties;\n* Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme;\n* Patients who are known to be HIV positive",{"count":317,"type":21},640,"The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma. Innate Pharma is a biotechnology company which discovers and develops therapeutic antibodies that exploit the innate immune system to improve cancer treatment. Thanks to this study, it will be possible to correlate clinical and immunological characteristics with the patient\\'s clinical features. The analyses generated will contribute to the design and improvement of innovative therapeutic antibodies acting on the immune system",[97,26,96,94,320],"Liver Cancer",[322,323,324,325,326,327,328,329,295,330,331,332,333,334],"Tumor microenvironment","Immuno-phenotyping","Immunohistochemistry","Ex-vivo functional assays","circulating tumor DNA","Gene sinatures","Breast cancer","Head and neck cancer","Liver cancer","Colorectal and gastric cancer","Lung cancer","lymphoma","leukemia","2025-02-13",{"date":337,"type":37},"2025-02-14",{"date":339,"type":21},"2025-04-30",{"date":341,"type":21},"2028-04-30",{"name":343,"class":44},"Assistance Publique Hopitaux De Marseille",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":78},"100557355","exploring-the-association-of-imaging-and-tumor-microenvironment-in-urologic-cancer-using-radiogenomic-approachradiogenomics-urinary-100557355","NCT06537037","Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）","Inclusion Criteria:\n\n1. Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027;\n2. Aged \\> 18 years old;\n3. At least one CT scan or MRI scan before treatment;\n4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.\n\nExclusion criteria：\n\n1. Poor image quality;\n2. Incomplete clinical data or loss of follow-up;\n3. Presence of another primary malignancy other than urologic cancer;\n4. Unclear pathological diagnosis。",{"count":351,"type":21},150,"This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.",[26],"2024-07-31",{"date":356,"type":37},"2024-08-05",{"date":358,"type":21},"2024-08",{"date":360,"type":21},"2027-08",{"name":362,"class":44},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":78},"100546618","prom-project-urology-100546618","NCT06397287","PROM Project Urology","Standardized Collection of Patient Reported Outcomes (PROs) in Everyday Clinical Practice","Inclusion Criteria:\n\n1. Patients treated at the Department of Urology\n2. ≥18 years of age\n3. Active Mail-account, use of smartphone\u002Ftablet\u002FPC\n4. Written informed consent\n\nExclusion Criteria:\n\n\\- Patients who cannot give written consent and\u002For do not have digital competence (e.g. no active e-mail account)",{"count":371,"type":21},47,"All patients undergoing urological surgery or treatment should receive standardized questionnaires on quality of life, satisfaction, pain and physical recovery. Indication-specific, individual pathways are set up, for example, for patients with localized prostate cancer, benign prostate enlargement, bladder dysfunction or erectile dysfunction. In combination with the clinical data, the PROM data should help to improve the quality of the results and, if necessary, adapt treatment pathways to patient needs.",[374,375,26],"Surgery","Urologic Diseases","2024-04-29",{"date":378,"type":37},"2024-05-02",{"date":380,"type":37},"2023-09-05",{"date":382,"type":21},"2045-09-05",{"name":384,"class":44},"Medical University of Graz",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":393,"sex":394,"minAge":53,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":57,"phases":397,"briefSummary":398,"conditions":399,"keywords":408,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":78},"100543557","the-man-van-project-100543557","NCT06357416","The Man Van Project","The Man Van Project: An Evaluation of the Effectiveness of a Mobile Outreach Screening Clinic Model for Earlier Detection of Prostate Cancer and Other Male Cancers","MV","Patients are eligible to be included in the research study if they are eligible to access the Man Van mobile outreach clinic, which is a novel clinical service delivered by The Royal Marsden Hospital NHS Foundation Trust. The inclusion and exclusion criteria have been designed to be as broad as possible, in order to include data from as many patients using the Man Van clinical service as possible.\n\nAs the primary purpose of the Man Van mobile outreach clinic is to screen for prostate, testicular, penile and other cancers that affect men, only men are eligible to be reviewed in the mobile outreach clinic hence only males will be recruited into this study.\n\nInclusion criteria for the Main Study\n\n1. Participating in the linked Man Van mobile outreach clinic\n2. Age ≥45 years\n3. Male\n\n   (The initial pilot study had a age criteria of ≥18 years, but this was amended).\n\n   MV-POCT\n\n   Inclusion Criteria: Any patient having a PSA and\u002For an HbA1c test as part of a Man Van work up, or via the our rapid diagnostics clinic.\n\n   MV-QualQ\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment.\n\n   MV-Eco\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment.\n\n   MV-PRS\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment and able to provide saliva samples.\n\n   MV-DNA\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment, and able to provide blood\u002Fsaliva samples.\n\n   MV MV-UctDNA\n\n   Inclusion Criteria: Any patient attending the Man Van for an assessment, and able to provide urine samples.\n\n   MV-SSI\n\n   Inclusion criteria:\n   * Aged \\> 18 and over (on date of invitation to participate)\n   * Works for healthcare organisation, other stakeholder or professional or potential man van patient who was not seen or relative of a Man Van patient\u002Fpotential patient\n\n   Exclusion criteria:\n   * Man van patient who has attended appointment\n\n   MV-TPP\n\n   Inclusion criteria:\n\n   Healthcare Professionals\n   * Aged \\> 18 and over (on date of invitation to participate)\n   * Speaks English\n   * Works within the UK\n   * Profession: GPs, Practice Staff (Nurses, Physician Assistants and Associates\n   * Healthcare assistants)\n   * Experienced in adopting new tests and guidelines into practice.\n   * Experienced in detecting, managing, and referring symptoms and asymptomatic patients with symptoms of prostate, pancreatic, GI cancer and\u002For are at an increased risk of developing these cancers.\n\n   Patients\n   * Aged \\> 18 and over (on date of invitation to participate)\n   * Speaks English\n   * Lives in the UK\n   * Patients with direct and in-direct experience with prostate, pancreatic, GI cancers.\n   * Patients at an increased risk of developing prostate, pancreatic, GI cancer in accordance with known risk factors, which includes age, smoking, being overweight or obese, family history and genetic factors, pancreatitis, and diabetes.\n\n   Other key stakeholders\u002Fprofessionals\n\n   • Aged \\> 18 and over (on date of invitation to participate)\n\n   • Speak English\n   * Works within the UK\n   * Professions: medical devices and biomedical researchers, scientists, representatives for major regulatory and funding bodies\n   * Knowledgeable of Early Detection initiatives (tests, outreach programes)\n\n   Exclusion criteria:\n\n   GPs\n\n   • Individuals who are unwilling to take part in the study.\n   * Individuals with no experience in adopting new cancer tests and guidelines into practice.\n   * Individuals with no experience in in detecting, managing, and referring patients with symptoms of cancer and\u002For are at an increased risk of developing prostate, pancreatic, GI cancer.\n   * Individuals who do not adequately understand verbal explanations or written information in English.\n\n   Patients • Individuals who are unwilling to take part in the study.\n\n   • Individuals who do not adequately understand verbal explanations or written information in English.\n\n   • Unable to provide written and verbal consent.\n\n   • No direct or indirect lived experience with prostate, pancreatic, GI cancers.\n\n   Non-clinical key stakeholders\u002Fprofessionals • Individuals who are unwilling to take part in the study • Individuals who are not familiar with cancer biomarkers and medical tests • Individuals with no knowledge of early detection\n\n   • Individuals who do not adequately understand verbal explanations or written information in English",true,"MALE",{"count":396,"type":21},4000,[90],"National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care at the site of their work and in their communities. The initial focus of this new standard of care clinic is to access workplaces with large manual workforces where large scale working from home is not possible. These will include logistics firms and bus companies. These companies employ large numbers of black and minority ethnic men who also have poorer outcomes with a range of other diseases, including Coronavirus disease (COVID)-19. The novel clinical service will collaborate with Unite (and other unions) as well as employers in order to reach our target groups effectively. There is also the opportunity to target higher risk groups e.g. Afro Caribbean communities whose rates of prostate cancer are 1 in 41 as well as occupational higher risk categories. The Man Van has the potential to swing the balance of evidence in favour of Prostate-Specific Antigen (PSA) screening, with a targeted screening program directed at high-risk groups including ethnic minorities and manual workers. Reasons for poorer outcomes amongst these groups are multi-factorial and complex. Levels of education are often a factor which can impact the understanding of the disease and how to seek assistance. Distrust of medical organisations has also been cited as a factor.\n\nThe aim of the Man Van mobile outreach service is to enable men access to a specific men's health service - focusing on general health and wellbeing (including BMI assessment, blood pressure, blood sugar\u002Fdiabetes checks etc) and a prostate check for those who raise concerns. This will include a PSA test where relevant. This will be the core data gathered from the project.\n\nPatients will receive PSA results in the 'Man Van' by a clinical nurse specialist with patients with raised PSA levels being referred into the standard rapid referral cancer pathways. Similar considerations will apply to men with haematuria detected on dip stick testing or who present with a testicular mass or penile lesion (both rare but important).\n\nThe clinical data generated from each routine health screening appointment will be analysed to determine the effectiveness of the Man Van mobile outreach model in identifying prostate and other male cancers and other co-morbidities much earlier than if patients had waited to present to their General Practitioner (GP) or other healthcare provider.\n\nPatients who receive an early diagnosis of clinically significant prostate cancer will have access to early curative treatments, which are typically less invasive and shorter in timescales. Similar interventions have shown large scale success in particular with breast and cervical cancer.\n\nThe NHS sees many patients accessing cancer care at a late stage. Reducing this trend is a key objective of the NHS Long Term Plan. The COVID-19 pandemic has further exacerbated health inequalities and mobile clinics can potentially be a model for alleviating this. To enable patients access to medical treatment earlier there is a need to make the 'seeking advice on men's health and prostate issues' less daunting, more normal and easily accessible. The 'Man Van' has the ability to do just that and it is anticipated that the findings of this research, using the data generated from each patient's routine health screening, will demonstrate that a mobile outreach model is more effective in identifying cancers at an earlier stage than 'traditional' diagnostic pathways.\n\nWe also hope to evaluate the Man Van with a qualitative study looking at the patient perspectives from those who utilise the Man Van.\n\nThe reasons for high risk in prostate cancer are heavily linked to genetics. This is an issue as there is less recruitment of high risk groups to studies. We hope to gather genetic data from a higher proportion of genetically susceptible men via the Man Van, which can be used in future to further genetic knowledge of prostate cancer.",[400,26,375,133,401,402,403,404,405,406,407],"Prostate Cancer","Diabetes","Hypertension","Mental Health Issue","Alcoholism","Smoking","Renal Cancer","Testis Cancer",[409,410],"mobile health","targeted screening",{"date":412,"type":37},"2024-05-01",{"date":414,"type":37},"2022-04-13",{"date":416,"type":21},"2026-12-01",{"name":418,"class":44},"Royal Marsden NHS Foundation Trust",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":393,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":78},"100530522","bank-of-biological-material-from-patients-and-healthy-donors-for-the-study-of-urological-and-uro-oncological-pathologies-100530522","NCT06187870","Bank of Biological Material From Patients and Healthy Donors for the Study of Urological and Uro-oncological Pathologies","Creation of a Bank of Biological Material From Patients and Healthy Donors (Biobank) for the Study of Urological and Uro-oncological Pathologies - URBBAN","Inclusion Criteria:\n\n* Male and female patients with an age \\> 18\n* Ability to read and sign the informed consent\n* patients affected by urological or uro-oncological diseases\n\nExclusion Criteria:\n\n* People with an age \\\u003C 18\n* Incapacity to read and sign the informed consent",{"count":427,"type":21},15000,"The project aims to collect fresh biological material derived both from surgical resections performed in diseases, neoplastic and otherwise, of urological relevance at the level of the prostate, bladder, kidney, testicle and genitourinary organs, and from peripheral blood or other fluids biological samples such as urine, seminal fluid, buccal mucosa, feces or saliva, when available.",[375,26,430],"Infertility","2024-01-08",{"date":433,"type":37},"2024-01-10",{"date":435,"type":37},"2010-10-07",{"date":437,"type":21},"2030-10-06",{"name":439,"class":44},"IRCCS San Raffaele",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":57,"phases":449,"briefSummary":450,"conditions":451,"keywords":457,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":78},"100508357","a-novel-imaging-protocol-in-use-to-identify-lymph-nodes-and-organs-of-interest-100508357","NCT05899361","A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest","A Pilot Study of a Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest for Surgical Dissection Within Urologic Regions of Interest.","Inclusion Criteria:\n\n* Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management\n* Subjects aged ≥ 18 years. Selected patients must have a confirmed or suspected diagnosis of disease in urologic regions of interest, with scheduled confirmatory surgical biopsy.\n* Subjects must have had either of the following scans: CT, PET or MR of acceptable quality at Brigham and Women's Hospital within the past year.\n* Subjects must also be scheduled to undergo lymph node dissection for a urologic cancer or organ removal of any of the following urologic regions of interest: Bladder, Prostate, Testicle, Ureter, Kidney, Urethra, Penis, and Scrotum\n* Subjects must also be scheduled to undergo a laparoscopic lymph node dissection and\u002For a urologic organ removal within any OR at BWH.\n\nExclusion Criteria:\n\n* Severely impaired renal function with an EGFR \\\u003C 30 mL\u002Fmin\u002Fbody surface area\n* Evidence of any significant, uncontrolled comorbid condition that could affect compliance with the protocol or interpretation of the results, which is to be judged at the discretion of the PI\n* History of hypersensitivity or other contraindication to contrast media\n* Contraindication to general anesthesia\n* Pregnancy",{"count":448,"type":21},10,[90],"This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe imaging will aid in reducing the complexity of both laparoscopic lymphadenectomy and\u002For organ removal in patients with a confirmed diagnosis of cancer in urologic regions of interest (Bladder, Prostate, Testicular, Kidney, Urethral, and Penis), by resulting in better visualization and more accurate localization of certain areas in the diseased organ or the diseased lymph node, and allowing for improved surgical and patient outcomes, fewer complications and better clinician performance.",[26,452,133,400,453,454,455,456],"Urologic Neoplasms","Testicular Cancer","Kidney Cancer","Urethral Cancer","Penile Cancer",[458,26,452,133,400,453,454,455,456],"Lymph Node Dissection",{"date":460,"type":37},"2023-10-24",{"date":462,"type":37},"2023-08-30",{"date":464,"type":21},"2026-12-25",{"name":466,"class":44},"Dana-Farber Cancer Institute"]